Developer docs
API playgroundTry for free, no card

Search company profiles

ROX Medical

Full company profile

uuid0004i1s

Namestring
ROX Medical
Websiteurl
roxmedical.com
Company typeenum
Private
Founded yearint
2004
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Clemente, United States
HQ citystring
San Clemente
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
COPD treatment devices, respiratory medical devices, interventional pulmonology, chronic lung disease therapy, minimally invasive pulmonary devices
Industry2 codes
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Interventional Pulmonology Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ROX Medical develops innovative medical devices for the treatment of chronic obstructive pulmonary disease (COPD). The company focuses on interventional device-based therapies intended for patients with chronic lung disease, operating within the respiratory medical device sector.

Differentiator
Functional benefit
Problem solved
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pulmonx develops the Zephyr endobronchial valve system for emphysema/COPD patients, the most directly comparable interventional device competitor to ROX Medical in the COPD treatment space.

TypeBroad incumbent
Description

Olympus owns the Spiration intrabronchial valve system for emphysema and is a broad respiratory/bronchoscopy incumbent offering overlapping interventional COPD capabilities as part of a larger portfolio.

TypeBroad incumbent
Description

PneumRx developed RePneu coils for emphysema and was acquired by BTG (later J&J); represents a comparable interventional COPD device pathway and a relevant consolidation benchmark.

TypeDirect peer
Description

CSA Medical markets the RejuvenAir metered cryospray system for chronic bronchitis, a direct niche peer in interventional device therapy for COPD-related chronic bronchitis.

TypeEmerging player
Description

Gala Therapeutics is developing interventional catheter-based therapies for chronic bronchitis and COPD, partially overlapping with ROX Medical's disease focus and interventional approach.

TypeEmerging player
Description

Aerin Medical develops minimally invasive office-based nasal airway and related ENT/airway interventions, an emerging player with partial thematic overlap in interventional airway procedures.

TypeDirect peer
Description

Broncus Medical develops interventional pulmonology tools (e.g., Archimedes virtual bronchoscopy and biopsy tools), serving the same interventional pulmonologist customer base treating COPD and emphysema.

TypeEmerging player
Description

Uptake Medical developed the InterVapor bronchoscopic thermal vapor ablation system for emphysema, a niche interventional COPD peer with comparable mechanism and clinical positioning.

9Holaira (now Nuvaira)
TypeEmerging player
Description

Nuvaira (formerly Holaira) developed targeted lung denervation for COPD, an interventional device peer targeting the same disease via a distinct mechanism, now backed by private capital.

TypeRegional player
Description

Inspire Medical Systems is an implantable neurostimulation company; though focused on sleep apnea rather than COPD, it serves as a relevant public-comparable for small-cap U.S. medtech companies commercializing implantable specialty devices.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ROX Medical

Interventional Pulmonology Devicesroxmedical.com

ROX Medical firmographics

Firmographics
Name
ROX Medical
Website
https://roxmedical.com
Company type
Private
Founded year
2004
Headcount range
11–50 employees
Ownership category
akta.pro rank

ROX Medical industry classification

Industry
Product category
Interventional Pulmonology Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAKANAE
COPD & Chronic Bronchitis Management
SECONDARYHLAKANAM
Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management

Keywords

  • COPD treatment devices
  • Respiratory medical devices
  • Interventional pulmonology
  • Chronic lung disease therapy
  • Minimally invasive pulmonary devices

Where ROX Medical is headquartered

Location

Headquarters

HQ city
San Clemente
HQ country
United States
HQ region
North America

Markets served

ROX Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

ROX Medical product offering

Product offering

Core offering

ROX Medical develops innovative medical devices for the treatment of chronic obstructive pulmonary disease (COPD). The company focuses on interventional device-based therapies intended for patients with chronic lung disease, operating within the respiratory medical device sector.

Differentiator

Problem solved

Functional benefit

Companies that use ROX Medical

Customer profile

Ideal customer profiles1 record

ROX Medical technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ROX Medical partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights3 records

ROX Medical competitors and assessment

Company assessment

Direct peers

  • Pulmonx: Pulmonx develops the Zephyr endobronchial valve system for emphysema/COPD patients, the most directly comparable interventional device competitor to ROX Medical in the COPD treatment space.
  • CSA Medical: CSA Medical markets the RejuvenAir metered cryospray system for chronic bronchitis, a direct niche peer in interventional device therapy for COPD-related chronic bronchitis.
  • Broncus Medical: Broncus Medical develops interventional pulmonology tools (e.g., Archimedes virtual bronchoscopy and biopsy tools), serving the same interventional pulmonologist customer base treating COPD and emphysema.

Broad incumbents

  • Olympus (Spiration): Olympus owns the Spiration intrabronchial valve system for emphysema and is a broad respiratory/bronchoscopy incumbent offering overlapping interventional COPD capabilities as part of a larger portfolio.
  • BTG / PneumRx (Johnson & Johnson): PneumRx developed RePneu coils for emphysema and was acquired by BTG (later J&J); represents a comparable interventional COPD device pathway and a relevant consolidation benchmark.

Emerging players

  • Gala Therapeutics: Gala Therapeutics is developing interventional catheter-based therapies for chronic bronchitis and COPD, partially overlapping with ROX Medical's disease focus and interventional approach.
  • Aerin Medical: Aerin Medical develops minimally invasive office-based nasal airway and related ENT/airway interventions, an emerging player with partial thematic overlap in interventional airway procedures.
  • Uptake Medical: Uptake Medical developed the InterVapor bronchoscopic thermal vapor ablation system for emphysema, a niche interventional COPD peer with comparable mechanism and clinical positioning.
  • Holaira (now Nuvaira): Nuvaira (formerly Holaira) developed targeted lung denervation for COPD, an interventional device peer targeting the same disease via a distinct mechanism, now backed by private capital.

Regional players

  • Inspire Medical Systems: Inspire Medical Systems is an implantable neurostimulation company; though focused on sleep apnea rather than COPD, it serves as a relevant public-comparable for small-cap U.S. medtech companies commercializing implantable specialty devices.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

ROX Medical social profiles

Digital presence

ROX Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ROX Medical leadership team

Management profile

Number of profiles

ROX Medical funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ROX Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ROX Medical

What does ROX Medical do?

ROX Medical develops innovative medical devices for the treatment of chronic obstructive pulmonary disease (COPD). The company focuses on interventional device-based therapies intended for patients with chronic lung disease, operating within the respiratory medical device sector.

When was ROX Medical founded?

ROX Medical was founded in 2004. It employs 11 to 50 people.

Where is ROX Medical based?

ROX Medical is headquartered in San Clemente, United States, in the North America region.

Who are ROX Medical's main competitors?

Direct peers on record are Pulmonx, CSA Medical and Broncus Medical. Broad incumbents are Olympus (Spiration) and BTG / PneumRx (Johnson & Johnson). Emerging players are Gala Therapeutics, Aerin Medical, Uptake Medical and Holaira (now Nuvaira). Inspire Medical Systems is listed as a regional player.

Does ROX Medical have an API?

No public API is recorded for ROX Medical.

What industry is ROX Medical in?

ROX Medical's product category is Interventional Pulmonology Devices. Its primary akta.pro industry code is HLAKANAE, COPD & Chronic Bronchitis Management, with a secondary code of HLAKANAM, Home Ventilation, Oxygen Therapy & Respiratory DME Clinical Management. Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireROX Medical, Inc. Hires Dr. Sackner-Bernstein as CMO and Executive VP of Clinical and Regulatory AffairsROX Medical, Inc. announced the appointment of Dr. Jonathan Sackner-Bernstein as Chief Medical Officer and Executive Vice President of Clinical and Regulatory Affairs. Dr. Sackner-Bernstein brings extensive experience as a cardiologist, former senior FDA official, and medical device executive who previously led teams at the FDA's Center for Devices and worked with DARPA. The company stated he was recruited to progress the ROX Coupler device toward broader market adoption as a potential standard-of-care treatment for hypertension.PR NewswireROX Medical Appoints Mike MacKinnon as Chief Executive OfficerROX Medical, a privately held medical device company, appointed Mike MacKinnon as Chief Executive Officer; MacKinnon previously led sales at Philips North America's Image Guided Technologies division following Philips' acquisition of Volcano. The company is developing the ROX Coupler, a small stent-like device that treats uncontrolled hypertension by diverting blood flow between arteries and veins in the upper thigh. ROX Medical is currently conducting the FDA-approved CONTROL HTN-2 pivotal clinical trial in the United States, while the device is already commercially available in Europe under CE mark.PR NewswireROX Medical Inc. Announces Sustained Improvements in Patients with Uncontrolled Hypertension Treated with the ROX CouplerROX Medical Inc. announced the 12-month outcomes of its ROX CONTROL HTN study, published in the journal Hypertension, showing sustained reductions in systolic blood pressure for patients with uncontrolled hypertension. The study reported a mean reduction of 25 mmHg in office systolic blood pressure and 13 mmHg in 24-hour ambulatory systolic blood pressure compared to baseline. These results support the potential of the ROX Coupler as a significant therapeutic advance, with the company currently enrolling patients in the pivotal CONTROL HTN-2 trial.PR NewswireROX Medical CONTROL HTN-2 Clinical Trial; First Procedure PerformedROX Medical, Inc. announced the first patient was treated in the CONTROL HTN-2 pivotal clinical trial for the ROX Coupler device at Brookwood Baptist Health Princeton Baptist Medical Center in Birmingham, Alabama. The trial will evaluate the device's ability to lower uncontrolled blood pressure through an arterio-venous anastomosis procedure at up to 30 study sites across the U.S. Prior European trials demonstrated a sustained mean blood pressure reduction of 27 mmHg at six months, with one-year results accepted for publication.PR NewswireROX Medical Raises $40M FinancingROX Medical raised $40M in Series E financing led by Novartis Venture Fund and Apple Tree Partners. The company will use the funds to initiate a U.S. pivotal clinical trial of its ROX Coupler device for uncontrolled hypertension. The device creates a connection between artery and vein in the upper leg.VC News DailyROX Medical Receives $40MROX Medical, a clinical-stage medical device company, has secured $40 million in Series E financing for its innovative Coupler therapy aimed at treating uncontrolled hypertension. The funding round was led by Novartis Venture Fund and Apple Tree Partners, accompanied by previous investors, and positions ROX Medical to initiate a pivotal clinical trial soon. This financing is viewed as a significant milestone for the company as it moves forward in the hypertension treatment market.FinSMEsROX Medical Closes $6M Financing RoundROX Medical closed a $6M financing round with backers Domain Associates and Versant Ventures. The company will use the funds to initiate an international trial of its ROX FLOW procedure for resistant hypertension. The procedure is not approved for use in the U.S.VC News DailyROX Medical Closes $6MROX Medical announced the closing of a $6M financing round led by existing investors Domain Associates and Versant Ventures. The funding will support an international randomized trial of the ROX FLOW procedure, a minimally invasive catheter-based treatment for resistant hypertension that reduces peripheral vascular resistance through a stent-like connection between the artery and vein in the upper leg. The FLOW procedure is not yet approved for use in the U.S., and pilot studies have demonstrated blood pressure reductions comparable to device therapies like renal denervation.